Related Experiment Video
Updated: Mar 31, 2026
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs
Walter Ombeni1, Appolinary R Kamuhabwa2
1Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Objective:
To determine the prevalence of dyslipidemia in HIV-infected patients using the first-line antiretroviral (ARV) drugs triple regimen.
Methods:
HIV-infected patients aged ≥15 years and attending Care and Treatment Clinic (CTC) at Muhimbili National Hospital, in Dar es Salaam, Tanzania, were recruited for the study. Blood samples from patients were collected during their regular visits at the CTC and assayed for determination of total cholesterol, triglycerides (TGs), high-density lipoprotein, low-density lipoprotein cholesterol, and CD4 counts.
Results:
The median CD4 count was 346 cells/mm(3) (2-2600). Triple therapy combinations of ARV drugs used by patients included zidovudine (ZDV)/lamivudine (3TC)/efavirenz (EFV; 42.4%), ZDV/3TC/nevirapine (NVP; 33.8%), tenofovir (TDF)/emtricitabine/EFV (19.9%), and TDF/3TC/EFV (3.9%). The overall prevalence of dyslipidemia in patients was 77.5%. There were varied prevalence of derangement of individual lipids among patients. Age, body mass index, CD4 count, sex, and duration of ARV drug use were the predictors of poor lipid profiles.
Conclusion:
The findings of this study indicate the need for routine monitoring of lipids among HIV-infected patients.
